Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,longTermDebt,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,netBorrowings,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,shortName,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,exchangeDataDelayedBy,priceHint,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,market,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,GOSS,220693000.0,75909696,44318000,,-59832000,,-59832000,11263000,0,-55581000,-55581000,,-4834000,,,,0,0,55581000,0,-4251000,,-59832000,-59832000,915414000.0,211817000.0,220693000.0,432510000.0,8000.0,566000.0,-695003000.0,274000.0,1070000.0,342453000.0,29982000.0,274000.0,14453000.0,416987000.0,63466000.0,100000.0,175670000.0,895000.0,-49923000.0,-66000.0,-50076000.0,271000.0,1354000.0,271000.0,-97205000.0,50000.0,-47450000.0,1297000.0,8118000.0,-138000.0,,,387005000.0,en-US,US,EQUITY,True,Delayed Quote,USD,"Gossamer Bio, Inc.",0.16541319,780351680,-3.7794116,2.2613287,15,America/New_York,EDT,-14400000,False,False,PREPRE,0,2,10.28,1630526402,0.34000015,9.92,10.41,9.83,478409,NMS,us_market,1.6536973,1630527401,10.45,0.17000008,3.4205246,9.83 - 10.41,9.94,0.0,0.0,14,9,finmb_548541911,NasdaqGS,"Gossamer Bio, Inc.",USD,505004,460585,3.2399998,0.46022725,7.04 - 14.468,-4.1880007,-0.28946644,7.04,14.468,1614259800,1614259800,1614259800,-3.552,-2.72,-3.11,-3.3054662,4.546,8.353143,1.926857,0.23067449,8.820906,1.459094,1.22,,,14.47,7.04,8.35,8.82,505k,460.58k,75.91M,,49.13M,11.66%,82.18%,11.09M,28.68,17.69%,14.82%,9.9M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-25.63%,-74.85%,,,,,-215.26M,-239.89M,-3.55,,405.92M,5.59,185.24M,83.93,13.91,4.55,-188.01M,-105.67M,Value,92121,Healthcare,195,8,7,"Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.",San Diego,858 684 1300,CA,8,1609372800,1625097600,6,United States,http://www.gossamerbio.com,86400,7,3013 Science Park Road,Biotechnology,Suite 200
t-1,GOSS,272084000.0,75909696,41827000,,-57641000,,-57641000,11346000,0,-53173000,-53173000,,-4780000,,,,0,0,53173000,0,-4468000,,-57641000,-57641000,907089000.0,210385000.0,272084000.0,482469000.0,8000.0,565000.0,-635171000.0,158000.0,1010000.0,439659000.0,29444000.0,158000.0,15612000.0,465847000.0,13638000.0,200000.0,173991000.0,1073000.0,12800000.0,-6565000.0,11968000.0,774000.0,-6373000.0,774000.0,-46396000.0,-242000.0,-58896000.0,1274000.0,8804000.0,-802000.0,,,436403000.0,en-US,US,EQUITY,True,Delayed Quote,USD,"Gossamer Bio, Inc.",0.16541319,780351680,-3.7794116,2.2613287,15,America/New_York,EDT,-14400000,False,False,PREPRE,0,2,10.28,1630526402,0.34000015,9.92,10.41,9.83,478409,NMS,us_market,1.6536973,1630527401,10.45,0.17000008,3.4205246,9.83 - 10.41,9.94,0.0,0.0,14,9,finmb_548541911,NasdaqGS,"Gossamer Bio, Inc.",USD,505004,460585,3.2399998,0.46022725,7.04 - 14.468,-4.1880007,-0.28946644,7.04,14.468,1614259800,1614259800,1614259800,-3.552,-2.72,-3.11,-3.3054662,4.546,8.353143,1.926857,0.23067449,8.820906,1.459094,1.22,,,14.47,7.04,8.35,8.82,505k,460.58k,75.91M,,49.13M,11.66%,82.18%,11.09M,28.68,17.69%,14.82%,9.9M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-25.63%,-74.85%,,,,,-215.26M,-239.89M,-3.55,,405.92M,5.59,185.24M,83.93,13.91,4.55,-188.01M,-105.67M,Value,92121,Healthcare,195,8,7,"Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.",San Diego,858 684 1300,CA,8,1609372800,1625097600,6,United States,http://www.gossamerbio.com,86400,7,3013 Science Park Road,Biotechnology,Suite 200
t-2,GOSS,320684000.0,75909696,38910000,,-64604000,,-64604000,15877000,0,-54787000,-54787000,,-12666000,,,,0,0,54787000,0,-9817000,,-64604000,-64604000,897607000.0,218749000.0,320684000.0,539433000.0,8000.0,565000.0,-577530000.0,599000.0,1027000.0,486055000.0,38650000.0,599000.0,16084000.0,522322000.0,26573000.0,200000.0,172386000.0,7508000.0,66650000.0,6974000.0,61100000.0,249000.0,67000.0,249000.0,24664000.0,51000.0,-36736000.0,1209000.0,18055000.0,-250000.0,-1778000.0,1778000.0,483672000.0,en-US,US,EQUITY,True,Delayed Quote,USD,"Gossamer Bio, Inc.",0.16541319,780351680,-3.7794116,2.2613287,15,America/New_York,EDT,-14400000,False,False,PREPRE,0,2,10.28,1630526402,0.34000015,9.92,10.41,9.83,478409,NMS,us_market,1.6536973,1630527401,10.45,0.17000008,3.4205246,9.83 - 10.41,9.94,0.0,0.0,14,9,finmb_548541911,NasdaqGS,"Gossamer Bio, Inc.",USD,505004,460585,3.2399998,0.46022725,7.04 - 14.468,-4.1880007,-0.28946644,7.04,14.468,1614259800,1614259800,1614259800,-3.552,-2.72,-3.11,-3.3054662,4.546,8.353143,1.926857,0.23067449,8.820906,1.459094,1.22,,,14.47,7.04,8.35,8.82,505k,460.58k,75.91M,,49.13M,11.66%,82.18%,11.09M,28.68,17.69%,14.82%,9.9M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-25.63%,-74.85%,,,,,-215.26M,-239.89M,-3.55,,405.92M,5.59,185.24M,83.93,13.91,4.55,-188.01M,-105.67M,Value,92121,Healthcare,195,8,7,"Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.",San Diego,858 684 1300,CA,8,1609372800,1625097600,6,United States,http://www.gossamerbio.com,86400,7,3013 Science Park Road,Biotechnology,Suite 200
t-3,GOSS,372101000.0,75909696,41846000,,-57812000,,-57812000,11448000,0,-53294000,-53294000,,-12666000,,,,0,0,53294000,0,-4518000,,-57812000,-57812000,884677000.0,212077000.0,372101000.0,584178000.0,8000.0,,-512926000.0,342000.0,861000.0,461956000.0,32607000.0,342000.0,17111000.0,566206000.0,93422000.0,500000.0,170823000.0,865000.0,20533000.0,737000.0,19959000.0,891000.0,245000.0,891000.0,-24106000.0,-26000.0,-44930000.0,1177000.0,9252000.0,-299000.0,1778000.0,-1778000.0,533599000.0,en-US,US,EQUITY,True,Delayed Quote,USD,"Gossamer Bio, Inc.",0.16541319,780351680,-3.7794116,2.2613287,15,America/New_York,EDT,-14400000,False,False,PREPRE,0,2,10.28,1630526402,0.34000015,9.92,10.41,9.83,478409,NMS,us_market,1.6536973,1630527401,10.45,0.17000008,3.4205246,9.83 - 10.41,9.94,0.0,0.0,14,9,finmb_548541911,NasdaqGS,"Gossamer Bio, Inc.",USD,505004,460585,3.2399998,0.46022725,7.04 - 14.468,-4.1880007,-0.28946644,7.04,14.468,1614259800,1614259800,1614259800,-3.552,-2.72,-3.11,-3.3054662,4.546,8.353143,1.926857,0.23067449,8.820906,1.459094,1.22,,,14.47,7.04,8.35,8.82,505k,460.58k,75.91M,,49.13M,11.66%,82.18%,11.09M,28.68,17.69%,14.82%,9.9M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-25.63%,-74.85%,,,,,-215.26M,-239.89M,-3.55,,405.92M,5.59,185.24M,83.93,13.91,4.55,-188.01M,-105.67M,Value,92121,Healthcare,195,8,7,"Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.",San Diego,858 684 1300,CA,8,1609372800,1625097600,6,United States,http://www.gossamerbio.com,86400,7,3013 Science Park Road,Biotechnology,Suite 200
